Egalet (EGLT) Announces Publication of Significant ARYMO ER Data
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Egalet Corporation (Nasdaq: EGLT) announced that results from a Category 3 oral human abuse potential (HAP) study and a Category 3 intranasal HAP study of product candidate ARYMO ER (morphine sulfate) extended-release tablets have been published in Pain Medicine, the official journal of the American Academy of Pain Medicine. These two primary publications of the oral and intranasal HAP studies report that, after manipulation and administration via the oral and intranasal routes, respectively, ARYMO ER had a significant reduction in maximum drug liking compared to crushed MS Contin® (morphine sulfate extended-release tablets) CII and placebo.
ARYMO ER was developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ARYMO ER uses Egalet's proprietary Guardian™ Technology, a polymer matrix tablet technology which is combined with a novel application of injection molding for the manufacturing of pharmaceutical tablets. This results in tablets with controlled-release properties as well as physical and chemical features that have been demonstrated to resist both common and rigorous methods of manipulation, in order to deter common routes of abuse. The U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date for a decision on ARYMO ER new drug application (NDA) is October 14, 2016.
"The oral and intranasal human abuse potential studies published in Pain Medicine highlight the broad and robust abuse-deterrent profile of ARYMO ER that, if approved, can help to limit accidental misuse and intentional abuse of morphine through both the manipulated oral and intranasal routes," said Jeffrey Dayno, MD, chief medical officer of Egalet. "With the vast majority of extended-release morphine products in abuseable forms, it is important that physicians have more treatment options like ARYMO ER with properties intended to deter abuse that, if approved, can potentially help to protect both patients and the surrounding communities."
Because of the hardness of ARYMO ER tablets, chewing would be very difficult so the tablets were maximally manipulated for the oral HAP study. The study was a single-center, double-blind, triple-dummy, four-way crossover study conducted to compare the relative abuse potential of manipulated ARYMO ER to crushed MS Contin and placebo. Thirty-eight subjects (ages 18 to 55) who were nondependent, recreational opioid users completed the study. The primary endpoint was maximum drug liking (Emax); key secondary outcomes included Overall Drug Liking, Take Drug Again and the Drug Effects Questionnaire. Pharmacokinetic (PK) parameters were also measured and Abuse Quotients (AQ) were reported.
Study highlights include:
- Manipulated ARYMO ER demonstrated a statistically significant reduction in maximum drug liking (Emax) compared to crushed MS Contin;
- Emax values were 67 for manipulated ARYMO and 74 for crushed MS Contin (P = 0.007)
- There was no significant difference in Emax drug liking between manipulated and intact ARYMO ER;
- Overall drug liking and Take Drug Again measures were numerically lower for manipulated ARYMO ER compared to crushed MS Contin, but did not reach statistical significance;
- Responses to 'Feeling High' and 'Good Effects' from the Drug Effects Questionnaire were both statistically significantly lower for manipulated ARYMO ER compared to crushed MS Contin;
- The Abuse Quotient (AQ = Cmax/Tmax), which measures the rate of rise of the opioid and is an indicator of abuse potential, was lower for both intact (5.7) and manipulated (16.4) ARYMO ER compared to crushed MS Contin (45.9);
- Adverse event profiles of ARYMO ER and MS Contin were similar and consistent with common opioid-related side effects; no serious adverse events were reported.
Intranasal StudyThis Category 3 abuse-deterrent intranasal HAP study was a single-center, randomized, double-blind, double-dummy, active and placebo-controlled, five period crossover study which assessed the abuse potential of ARYMO ER versus MS Contin in 46 nondependent, recreational opioid users when taken intranasally. The primary objective was to compare drug liking after subjects snorted manipulated ARYMO ER versus crushed MS Contin. Since ARYMO ER is an extremely hard tablet and difficult to reduce to small particle sizes amenable to snorting (based on the outcome of the first phase, physical tampering, of the Category 1 abuse-deterrent studies for ARYMO ER), the manipulation procedure involved a multi-step process using both mechanical and electrical instruments to prepare the product to be dosed intranasally. In addition, the manipulated product was then sieved to yield particle sizes that would be small enough for the subjects to snort. Both of these outputs, the full particle sizes and the sieved/small particle sizes, were included and evaluated as separate arms in the study. In comparison, MS Contin was prepared via a single-step, mechanical manipulation process, which did not require sieving as all particle sizes were small enough to snort.
Top-line results from the study include:
- After maximal manipulation, ARYMO ER demonstrated a statistically significant reduction in maximum drug liking (Emax; primary endpoint) compared to crushed MS Contin (p < 0.001);
- This was seen in both of the ARYMO ER arms: manipulated and all particle sizes snorted as well as manipulated then filtered with only the smaller particle sizes snorted
- ARYMO ER was statistically superior to MS Contin on the secondary endpoints of 'overall drug liking' and 'take drug again' (p < 0.001 for both endpoints);
- On the measures of 'overall drug liking' and 'take drug again,' both of the ARYMO ER manipulated arms had scores similar to placebo;
- The 'Abuse Quotient' (a pharmacokinetic indicator of abuse potential, with higher scores suggestive of greater abuse potential), for each of the treatment arms was as follows:
- 37.2 for manipulated MS Contin
- 9.2 for manipulated ARYMO ER (all particle sizes)
- 2.3 for manipulated ARYMO ER (filtered/small particle sizes)
- 5.5 for intact oral ARYMO ER;
- Adverse event profiles of ARYMO ER and MS Contin were similar and consistent with common opioid-related side effects except for nasal irritation; no serious adverse events were reported.
Premarketing abuse-deterrent studies have not been proven to predict real world misuse and abuse of opioids. If approved, this would be evaluated for ARYMO ER in a post-marketing abuse-deterrent study to assess its impact on the misuse and abuse of extended-release morphine products.
To view the full publications, please visit the journal Pain Medicine at http://painmedicine.oxfordjournals.org/.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flex Pharma (FLKS) to Prioritize Phase 2 Clinical Programs in Severe Neurological Diseases
- Microsoft (MSFT) Names Kevin Scott as CTO
- TG Therapeutics (TGTX) Receives Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 to Treat DLBCL
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!